Tag Archives: Amgen

Lilly’s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS (Reuters) – Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.… Read More »

Locked in a Sensipar patent fight, Teva rolled its generic anyway—and then Amgen settled

Amgen has been sweating potential copycats to its blockbuster calcium reducer Sensipar. But thanks to a patent deal with Teva, yet another challenger will have to wait until 2021 to sell its generic knockoff. This deal features a unique wrinkle, though. Teva had already launched its version, according to Bernstein analyst Ronny Gal, costing Amgen tens… Read More »